Skip to main content
Fig. 6 | Cancer & Metabolism

Fig. 6

From: Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma

Fig. 6

Proposed model of anti-tumor mechanism for metformin in rituximab-sensitive and resistant B-cell lymphoma. Based on our work, we have formulated a model by which we hypothesize metformin induces in its anti-tumor effects. Metformin inhibits proliferation via C-Myc resulting in G1 cell cycle arrest. Metformin causes increased ROS production and loss of mitochondrial membrane potential resulting in apoptosis. Metformin enhances rituximab-mediated ADCC and to a lesser degree CMC

Back to article page